Cell and Gene Therapy Deals: Financings, Partnering, M&A, Technology Transfers, IPOs, and Other Developments
Cell and Gene Therapy Funding Reached $70 Billion in 2021. How Can You Keep Up with the Activity in this Industry?
A lot of attention is being given to the areas related to cell and gene therapy (CGT) recently. There are now many approved therapies with proven track records. As the tools have lowered the barriers to entry for the industry, over a thousand companies have been created or become involved. Fortunately, Kalorama Information has been tracking every significant development in CGT as part of its Cell and Gene Therapy Business Outlook Newsletter.
In concert with the technologies progressing and the proven benefits, CGT-related companies have received growing amounts of funding—and it appears likely that the trend will continue. How do you keep up with this high-interest field?
This Kalorama Information report, Cell and Gene Therapy Deals Analysis, analyzes the deals, including:
- IPO and FPO Deals
- SPAC Deals
- Venture Capital and Private Funding
- Strategic Investments
- Mergers & Acquisitions (M&A)
- Technology and Research Collaborations
- Licensing Deals
- Manufacturing and Supply Chain Deals
- Public Outreach, Consumer Education, & Philanthropy
- Distribution & Co-marketing Deals
- Restructurings, Joint Ventures, Terminations and Spinoffs
- Other Types of Deals Impacting Cell and Gene Therapy
This report categorizes hundreds of cell and gene therapy deals into a usable format. Charts help to illustrate the different types of deals and frequency of different types of deals and the how the deals activity in 2021 changed per quarter.
This is an essential resource that every market watcher in Cell and Gene Therapy will need. For updated information on cell and gene therapy deals on a regular basis, add Cell and Gene Therapy Business Outlook Newsletter to your purchase. Your sales representative can assist with your purchase of both this detailed report and regularly updated information through a newsletter subscription.
- Executive Summary
- Introduction
- $70.8 Billion in Funding During 2021
- Table Total Quarterly Funding, By 2021 Quarter, By Type of Funding [M&A; Venture Capital/Private; IPO/FPO; and SPAC] (note: also Strat. Inv. $600M min) ($M) (%)
- Table Total Quarterly Funding, By 2021 Quarter, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M)
- Quarterly Funding in 2021
- Table Q1 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Table Q2 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Table Q3 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- Table Q4 2021 Funding Share, By Type of Funding [Mergers and Acquisitions/M&A; Venture Capital/Private; IPO/FPO; and SPAC] ($M) (%)
- 916 Total CGT Announcements from January 2021 through January 2022
- Table Quarterly Count of Deals, By 2021 Quarter, By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co- Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number) (%)
- UUptick in Collaborations, Acquisitions, and Manufacturing/Supply Chain Deals Highlight Activity in Cell and Gene Therapy
- Table Most Frequent Types of Deals, by 2021 Quarter, by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)
- A Look at Less Frequent CGT Deal Types
- Table Lower Frequency Deal Types, by 2021 Quarter, by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
- Table Monthly Count of Deals [Jan 2021-Jan 2022], By Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; Manufacturing, Supply Chain; Outreach, Philanthropy, Education; Distribution, Co- Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number, n=916) (%)
- Table Total Deals per Month, January 2021-January 2022 (total number)
- Table Most Frequent Types of Deals, by Month [January 2021-January 2022], by Category [Technology/Research/Strategic Collaboration; Venture Capital/Private Investment; Acquisition, Merger, Strategic Investment; Licensing; Public Offering/SPAC; and Manufacturing, Supply Chain] (total number)
- Table Lower Frequency Deal Types, by Month [January 2021-January 2022], by Category [Outreach, Philanthropy, Education; Distribution, Co-Marketing; Spinout, Restructure; Conclude/Terminate Deal; Joint Venture; and Settle Litigation] (total number)
- Table Acquisition Amount, by Quarter [January 2021-January 2022] ($M)
- Table Venture Capital/Private Funding Round Amount, by Quarter [January 2021-January 2022] ($M)
- Table IPO/FPO Amount, by Quarter [January 2021-December 2021] ($M)
- Table SPAC Amount, 2021 ($M)
- Venture Capital & Private Funding
- VC/Private Funding in Flux
- Table Quarterly Venture Capital/Private Total Funding, By Quarter and Jan 2022 [Jan 2021-Jan 2022], By Region [North America, Europe, APAC, Rest of World] ($M)
- Table Quarterly Venture Capital/Private Total Funding, By Quarter [January 2021-January 2022], By Region [North America, Europe, APAC, Rest of World] ($M)
- Table Venture Capital/Private Funding Round Amount, By Quarter [January 2021-January 2022], ($M)
- Table Venture Capital/Private, January 2022
- Table Venture Capital/Private, Q4 2021
- Table Venture Capital/Private, Q3 2021
- Table Venture Capital/Private, Q2 2021
- Table Venture Capital/Private, Q1 2021
- VC/Private Funding in Flux
- Strategic Investments
- Strategic Investments in Cell and Gene Therapy
- Table Strategic Investments, January 2021-January 2022
- Strategic Investments in Cell and Gene Therapy
- IPOs, FPOs, &SPACs
- North America Sees Majority of Proceeds from IPOs, FPOs, and SPACs
- Table Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe) ($M)
- Table Quarterly IPO/FPO Funding, By Region [North America, APAC, and Europe) ($M)
- Table IPO/FPO Amount, By Quarter [January 2021-January 2022] ($M)
- Table Disclosed Quarterly SPAC Funding Portion ($M)
- Table Disclosed Q1-Q4 and January 2022 SPAC Funding Portion ($M)
- Table IPO/FPO Deals, Q4 2021
- Table IPO/FPO Deals, Q3 2021
- Table IPO/FPO Deals, Q2 2021
- Table IPO/FPO Deals, Q1 2021
- Table SPAC Piece, January 2021-January 2022 ($M)
- Table SPAC Amount, 2021 ($M)
- North America Sees Majority of Proceeds from IPOs, FPOs, and SPACs
- Mergers & Acquisitions (M&A)
- Spike in M&A Activity During Q3 2021
- Table Quarterly Merger and Acquisition Totals, January 2021-January 2022 ($M)
- Table Acquisition Amount, By Quarter [January 2021-January 2022], ($M)
- Table Mergers and Acquisitions, January 2022 ($M)
- Table Mergers and Acquisitions, Q4 2021 ($M)
- Table Mergers and Acquisitions, Q3 2021 ($M)
- Table Mergers and Acquisitions, Q2 2021 ($M)
- Table Mergers and Acquisitions, Q1 2021 ($M)
- Spike in M&A Activity During Q3 2021
- Technology/Research/Strategic Collaborations
- CGT Market Sees a Broad Variety of Collaborations
- Table Technology/Research/Strategic Collaboration Deals, January 2021-January 2022
- CGT Market Sees a Broad Variety of Collaborations
- Licensing
- A Look at Licensing in the Cell and Gene Therapy Market
- Table Licensing Deals, January 2021-January 2022
- A Look at Licensing in the Cell and Gene Therapy Market
- Manufacturing and Supply Chain
- Examining Manufacturing and Supply Chain Management Activity in CGT
- Table Manufacturing and Supply Chain Deals, January 2021-January 2022
- Examining Manufacturing and Supply Chain Management Activity in CGT
- Public Outreach, Consumer Education, &Philanthropy
- CGT Market Has Dozens of Announcements Related to Public Outreach, Patient/Consumer Education, and Philanthropy
- Table Outreach, Education, &Philanthropy Deals, January 2021-January 2022
- CGT Market Has Dozens of Announcements Related to Public Outreach, Patient/Consumer Education, and Philanthropy
- Distribution & Co-Marketing
- A Look at CGT Distribution and Co-Marketing Deals
- Table Distribution & Co-Marketing Deals, January 2021-January 2022
- A Look at CGT Distribution and Co-Marketing Deals
- Other - Conclusion, Restructuring, JV, Termination, Spinoffs
- A Look at Other Types of Deals Impacting Cell and Gene Therapy
- Table Restructuring, JV, Termination, Spinoffs Deal, January 2021-January 2022
- A Look at Other Types of Deals Impacting Cell and Gene Therapy
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook